Home
Home

age-related macular degeneration

Regeneron Shareholders Watching Optina Trial Closely

Regeneron Shareholders Watching Optina Trial Closely
Seeking Alpha

Regeneron Pharma raises sales forecast for Eylea

Regeneron Pharma raises sales forecast for Eylea
Yahoo/AP

Regeneron's Flagship Drug Treats Blindness In Seniors

Regeneron's Flagship Drug Treats Blindness In Seniors
Investors.com

Age-Related Macular Degeneration: A Promising Investment Opportunity

Age-Related Macular Degeneration: A Promising Investment Opportunity
Seeking Alpha

2 Drug Approvals and Shares Drop? That's Biotech!

2 Drug Approvals and Shares Drop? That's Biotech!
Motley Fool

Valeant buys Visudyne drug from QLT; QLT stock jumps

Valeant buys Visudyne drug from QLT; QLT stock jumps
Reuters

Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration

Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Yahoo/PR NewsWire

VA Reinstates Avastin Usage For Eye Disease

VA Reinstates Avastin Usage For Eye Disease
Pharmalot

Regeneron Soars on Eye-Drug Rival Setback

Regeneron Soars on Eye-Drug Rival Setback
TheStreet.com

Regeneron Pharmaceuticals Shares Plunged: What You Need to Know

Regeneron Pharmaceuticals Shares Plunged: What You Need to Know
Motley Fool